eligibility_summary
Adults (≥18) with confirmed breast cancer and brain metastases (imaging/pathology), complete records, and prior SG treatment (any line/timing). No limits on lesion number/size or meningeal disease. Require consent (or guardian), stable vitals (no uncontrolled severe infection, recent/uncontrolled seizures, or advanced heart/liver/kidney failure), and feasible follow-up. Exclude active other primary cancer <5y, inability to consent/follow-up without guardian, interventional trial, or other safety/quality concerns.
trial_source
clinical_trials.gov from Dec 2, 2025
annotation_status
ai
ai_summary
Intervention: Sacituzumab govitecan (SG, IMMU-132, hziy), a Trop‑2–directed antibody–drug conjugate (targeted cytotoxic). Mechanism: a humanized anti–Trop‑2 IgG linked via a hydrolyzable linker to SN‑38 (the active metabolite of irinotecan), a topoisomerase I inhibitor. After binding Trop‑2 on tumor cells and internalization, SN‑38 is released to inhibit topo I, causing DNA damage and apoptosis, the membrane‑permeable payload can also exert a bystander effect. Targets: Trop‑2–expressing breast cancer cells (including brain metastases). Pathways: Trop‑2 surface antigen–mediated targeting and DNA replication/repair machinery via topoisomerase I inhibition. Study: Multicenter, observational real‑world cohort in China evaluating intracranial efficacy (iORR, iPFS) and safety of SG in adults with breast cancer brain metastases.